ATEM ® Ipratropium bromide

ATEM ® is a drug based on Ipratropium bromide

THERAPEUTIC GROUP: Medicines for obstructive disorders of the respiratory tract

Indications ATEM ® Ipratropium bromide

ATEM ® is indicated in the treatment of obstructive respiratory tract disorders such as bronchial asthma and chronic obstructive pulmonary disease.

Mechanism of action ATEM ® Ipratropium bromide

Ipratropium bromide, active principle of ATEM ®, is a quaternary derivative of atropine, used in the clinical setting for the treatment of obstructive respiratory tract disorders.
In fact, once inhaled it is able to interact with the bronchial muscarinic receptors, exerting a particularly rapid anticholinergic action in the timing of onset.
The binding of Ipratropium bromide to the muscarinic receptors m2 and M3 expressed by the bronchial musculature, antagonizing the effect of acetylcholine, determines a bronchodilator action such as to improve the patency of the upper airways, restoring an adequate ventilatory flow which persists for about 4- 6 hours from hiring.
The low systemic absorption of the active ingredient also makes the therapy particularly safe, significantly limiting the risk of potential side effects.

Studies carried out and clinical efficacy

HYPRATROPIO BROMIDE AND RISK OF ARRHTHMIA
Pharmacotherapy. 2013 Aug 5. doi: 10.1002 / phar.1336. [Epub ahead of print]

Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Case-Control Study.

Adimadhyam S, Schumock GT, Walton S, Joo M, McKell J, Lee TA.

Very recent study that demonstrates how the use of Ipratropium bromide may be associated with a greater risk of arrhythmia in patients with asthma aged between 12 and 14 years.

THE BROMIDE HYPRATROPIO FOR THE COMMON COOLER
Cochrane Database Syst Rev. 2013 Jun 19; 6: CD008231. doi: 10.1002 / 14651858.CD008231.pub3.

Intranasal ipratropium bromide for the common cold.

AlBalawi ZH, Othman SS, Alfaleh K.

Interesting work that demonstrates how the intranasal administration of Ipratropium bromide can lead to a significant improvement in rhinorrhea in patients suffering from the common cold. Also this action would be determined by the anticholinergic action of the active principle on the muciparous glands present in the nasal mucosa.

BROMIDE HYPRATROPIO IN ASSOCIATION WITH SALBUTAMOL
Mymensingh Med J. 2013 Apr; 22: 345-52.

Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma.

Hossain AS, Barua UK, Roy GC, Sutradhar SR, Rahman I, Rahman G.

Work that demonstrates how the association between Sulbutamol and Ipratropium bromide can present a more effective bronchodilator action than monotherapies, resulting in a clear improvement in asthmatic symptoms

Method of use and dosage

ATEM ®
Dosed aerosol of 4 mg of Ipratropium bromide (20 mcg per inhalation)
Solution for aerosol use of 0.0250 g of Ipratropium bromide.
Treatment with ATEM ® should be calibrated by your physician on the basis of the patient's clinical condition and his / her responsiveness to therapy.
Generally it is recommended to apply 2 sprays 3 times a day or 1 ml for each aerosol session 1-2 times a day.

ATEM ® warnings Ipratropium bromide

Treatment with ATEM ® should be defined and supervised by your doctor, considering the possible presence of contraindications to the use of this product and therefore its prescribing appropriateness.
The patient should also carefully respect all the instructions provided by the doctor, taking care to inform him promptly of the appearance of unwanted side effects rather than worsening of the clinical picture.
It is recommended to store the drug out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the absence of studies capable of characterizing the safety profile of Ipratropium bromide for the health of the fetus and infant, it would be advisable to limit the use of ATEM ® during pregnancy and in the subsequent period of breastfeeding, exclusively to cases of real need and always under the strict supervision of your doctor.

Interactions

No drug interactions worthy of clinical note are currently known.

Contraindications ATEM ® Ipratropium bromide

The use of ATEM ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with glaucoma, prostatic hypertrophy or urinary retention syndromes or intestinal obstruction.

Undesirable Effects - Side Effects

ATEM ® therapy is generally safe and well tolerated.
Adverse reactions such as dry mouth, dizziness, heart rhythm disturbances, constipation and urinary retention symptoms were observed only rarely, but they disappeared immediately after discontinuing the drug.

Note

ATEM ® is a prescription drug.

The information on ATEM ® Ipratropium bromide published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.